Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EPS (Basic): 2018-2025

Historic EPS (Basic) for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$0.26.

  • Whitehawk Therapeutics' EPS (Basic) rose 43.48% to -$0.26 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.14, marking a year-over-year increase of 106.14%. This contributed to the annual value of -$2.36 for FY2024, which is 3.28% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its EPS (Basic) stood at -$0.26 for Q3 2025, which was up 65.79% from -$0.76 recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' EPS (Basic) peaked at $6.96 during Q4 2021, and registered a low of -$9.17 during Q3 2021.
  • For the 3-year period, Whitehawk Therapeutics' EPS (Basic) averaged around -$0.36, with its median value being -$0.60 (2023).
  • In the last 5 years, Whitehawk Therapeutics' EPS (Basic) tumbled by 645.53% in 2021 and then spiked by 370.59% in 2025.
  • Whitehawk Therapeutics' EPS (Basic) (Quarterly) stood at $6.96 in 2021, then slumped by 106.90% to -$0.48 in 2022, then dropped by 25.00% to -$0.60 in 2023, then decreased by 13.33% to -$0.68 in 2024, then skyrocketed by 43.48% to -$0.26 in 2025.
  • Its last three reported values are -$0.26 in Q3 2025, -$0.76 for Q2 2025, and $1.84 during Q1 2025.